"Whenever I bake cookies, I pretty much exclusively use nonstick baking mats in lieu of parchment paper," says Jesse Szewczyk ...

One of its major takeaways is that if the government's health insurance program were to cover weight loss drugs like Eli Lilly's Zepbound starting in January 2026, it would add a total of $35 ...

Maxwells Trading, the restaurant in Chicago by three-time James Beard-nominated chef and partner Erling Wu-Bower, makes ...

Bloomberg / Contributor / Getty Images Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list ...

Eli Lilly has finally made enough supply of its popular medicine tirzepatide to meet soaring demand, which should help the company widen its share of the booming weight-loss drug market.

The Food and Drug Administration said Wednesday that the shortage of Lilly’s Zepbound and Mounjaro is resolved. The agency added that there are “legal restrictions on making copies of FDA ...

Eli Lil­ly’s block­buster GLP-1 drug tirzepatide is fi­nal­ly back on track in the US af­ter two years of in­ter­mit­tent short­ages dri­ven by high de­mand, the … ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have ...

BioAge Labs is working on therapies for obesity as well as aging. It has plenty of cash, and it's collaborating with Eli Lilly and Novo Nordisk. Its pipeline programs aren't as early-stage as ...

(Reuters) -The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling ...

The article has been corrected. The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday. Eli Lilly’s ...

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no longer ...